Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

865 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 Antibodies.
Santarpia M, Aguilar A, Chaib I, Cardona AF, Fancelli S, Laguia F, Bracht JWP, Cao P, Molina-Vila MA, Karachaliou N, Rosell R. Santarpia M, et al. Among authors: aguilar a. Cancers (Basel). 2020 Jun 5;12(6):1475. doi: 10.3390/cancers12061475. Cancers (Basel). 2020. PMID: 32516941 Free PMC article. Review.
Osimertinib and dihydroartemisinin: a novel drug combination targeting head and neck squamous cell carcinoma.
Chaib I, Cai X, Llige D, Santarpia M, Jantus-Lewintre E, Filipska M, Pedraz C, Cui J, Yang J, Miao J, Sun R, Bracht JWP, Ito M, Codony-Servat J, Karachaliou N, Aguilar A, Rosell R, Cao P. Chaib I, et al. Among authors: aguilar a. Ann Transl Med. 2019 Nov;7(22):651. doi: 10.21037/atm.2019.10.80. Ann Transl Med. 2019. PMID: 31930052 Free PMC article.
KRAS inhibitors, approved.
Rosell R, Aguilar A, Pedraz C, Chaib I. Rosell R, et al. Among authors: aguilar a. Nat Cancer. 2021 Dec;2(12):1254-1256. doi: 10.1038/s43018-021-00289-3. Nat Cancer. 2021. PMID: 35121930 No abstract available.
Author Correction: KRAS inhibitors, approved.
Rosell R, Aguilar A, Pedraz C, Chaib I. Rosell R, et al. Among authors: aguilar a. Nat Cancer. 2022 Apr;3(4):518. doi: 10.1038/s43018-022-00372-3. Nat Cancer. 2022. PMID: 35379985 No abstract available.
Tumor mutational burden as predictive factor of response to immunotherapy.
Gonzalez-Cao M, Viteri S, Karachaliou N, Aguilar A, García-Mosquera JJ, Rosell R. Gonzalez-Cao M, et al. Among authors: aguilar a. Transl Lung Cancer Res. 2018 Dec;7(Suppl 4):S358-S361. doi: 10.21037/tlcr.2018.10.03. Transl Lung Cancer Res. 2018. PMID: 30705855 Free PMC article. No abstract available.
Multiplex Detection of Clinically Relevant Mutations in Liquid Biopsies of Cancer Patients Using a Hybridization-Based Platform.
Giménez-Capitán A, Bracht J, García JJ, Jordana-Ariza N, García B, Garzón M, Mayo-de-Las-Casas C, Viteri-Ramirez S, Martinez-Bueno A, Aguilar A, Sullivan IG, Johnson E, Huang CY, Gerlach JL, Warren S, Beechem JM, Teixidó C, Rosell R, Reguart N, Molina-Vila MA. Giménez-Capitán A, et al. Among authors: aguilar a. Clin Chem. 2021 Mar 1;67(3):554-563. doi: 10.1093/clinchem/hvaa248. Clin Chem. 2021. PMID: 33439966
The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC.
Rodríguez-Abreu D, Cobo M, García-Román S, Viteri-Ramírez S, Jordana-Ariza N, García-Peláez B, Reguart N, Aguilar A, Codony-Servat J, Drozdowskyj A, Molina-Vila MA, d'Hondt E, Rosell R. Rodríguez-Abreu D, et al. Among authors: aguilar a. Lung Cancer. 2022 Feb;164:8-13. doi: 10.1016/j.lungcan.2021.12.014. Epub 2021 Dec 23. Lung Cancer. 2022. PMID: 34971901 Clinical Trial.
865 results